Abeona Therapeutics Inc.
ABEO
$5.75
-$0.15-2.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -100.00% | 227.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -100.00% | 227.72% |
| Cost of Revenue | 10.67% | 1.65% | 130.85% | 75.83% | 47.59% |
| Gross Profit | -21.37% | -11.25% | -194.18% | -110.44% | -40.14% |
| SG&A Expenses | 46.92% | 57.08% | 48.51% | 38.54% | 29.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.92% | 24.20% | 20.19% | 16.76% | 22.88% |
| Operating Income | -37.86% | -33.22% | -29.31% | -26.02% | -17.77% |
| Income Before Tax | 42.36% | -17.62% | -58.84% | -33.79% | -186.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.36% | -17.62% | -58.84% | -33.79% | -186.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.36% | -17.62% | -58.84% | -33.79% | -186.48% |
| EBIT | -37.86% | -33.22% | -29.31% | -26.02% | -17.77% |
| EBITDA | -39.66% | -35.49% | -32.26% | -29.62% | -21.15% |
| EPS Basic | 72.63% | 30.73% | 9.11% | 30.11% | 6.57% |
| Normalized Basic EPS | 73.10% | 32.23% | 8.36% | 29.65% | -10.63% |
| EPS Diluted | 58.65% | 13.42% | -9.01% | 15.16% | 6.57% |
| Normalized Diluted EPS | 71.86% | 30.70% | 6.70% | 28.29% | -10.63% |
| Average Basic Shares Outstanding | 94.68% | 92.11% | 92.93% | 115.15% | 125.22% |
| Average Diluted Shares Outstanding | 106.38% | 105.24% | 108.27% | 135.64% | 125.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |